Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ArtemiCoffee in Advanced Ovarian Cancer
NCT04805333Phase 1Completed
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of artemisia annua in ovarian cancer (5 arms). Primary endpoint: Recommended Phase II Dose at 150 days. Started Mar 2021; status: completed.
02
Drugs
artemisia annua
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04805333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805333.